Cited by 1,059Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Open access

Turke, Alexa B., Zejnullahu, Kreshnik, Wu, Yi-Long, Song, Youngchul, Dias-Santagata, Dora, Lifshits, Eugene, Toschi, Luca, Rogers, Andrew, Mok, Tony, Sequist, Lecia, Lindeman, Neal I., Murphy, Carly, Akhavanfard, Sara, Yeap, Beow Y., Xiao, Yun, Capelletti, Marzia, Iafrate, A. John, Lee, Charles, Christensen, James G., Engelman, Jeffrey A., Jänne, Pasi A.·2010·Cancer Cell

DOI 10.1016/j.ccr.2009.11.022PMC PMC2980857

Open this paper in CoChat — free account Open PDF

Abstract

MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand, HGF, also induces drug resistance, but through GAB1 signaling. Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, we identify subpopulations of cells with MET amplification prior to drug exposure. Surprisingly, HGF accelerates the development of MET amplification both in vitro and in vivo. EGFR kinase inhibitor resistance, due to either MET amplification or autocrine HGF production, was cured in vivo by combined EGFR and MET inhibition. These findings highlight the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2009.11.022

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“Secondary mutations in EGFR itself, including the EGFR T790M ‘‘gatekeeper’’ mutation is observed in 50% of resistance cases, and amplification of the MET oncogene is observed in 20% of resistance cases (Balak et al., 2006; Bean et al., 2007; Engelman et al., 2007b; Kobayashi et al., 2005; Kosaka et al., 2006; Pao et a…”
Background
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“To date, resistance mechanisms have predominately involved secondary genomic alterations in the target kinase that alter either the physical (such as steric hindrance) or biochemical (change in ATP affinity) properties of the receptor and result in drug resistance (Gorre et al., 2001; Shah et al., 2002; Yun et al., 20…”
Background
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Self-citation

Show all 37 references

Sorted by citations

Items 501–600 of 1,000

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Spagnolo, C. C., Ciappina, G., Giovannetti, E., Squeri, A., Granata, B., Lazzari, C., Pretelli, G., Pasello, G., & Santarpía, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210119 · Cited by 36
Immune checkpoint inhibitors in metastatic melanoma therapy (Review)
Shah, V., Panchal, V. S., Shah, A., Vyas, B., Agrawal, S. P., & Bharadwaj, S. P. (2024) · Medicine International · doi:10.3892/mi.2024.137 · Cited by 37
EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)
Tian, Z., Cen, L., Feng, W., Dong, J., Huang, Y., Han, Y., Wang, Z., Deng, J., & Jiang, Y. (2025) · Oncology Letters · doi:10.3892/ol.2025.15121 · Cited by 34
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Santarpía, M., Gil, N., & Rosell, R. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1055252 · Cited by 34
The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1
Voena, C., Giacomo, F. D., Panizza, E., D’Amico, L., Boccalatte, F. E., Pellegrino, E., Todaro, M., Recupero, D., Tabbò, F., Ambrogio, C., et al. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.7 · Cited by 35
EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis
Han, C., Ma, J.-T., Li, F., Zhao, J., Wei, J., Zhou, Y., & Zou, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.012 · Cited by 33
Biological significance and targeting of c-Met tyrosine kinase receptor in cancer
Goetsch, L. (2012) · Frontiers in bioscience · doi:10.2741/4114 · Cited by 34
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer
Mehra, R., Serebriiskii, I. G., Dunbrack, R. L., Robinson, M. K., Burtness, B. A., & Golemis, E. A. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.08.002 · Cited by 34
Personalized Therapy of Non-small Cell Lung Cancer (NSCLC)
Gadgeel, S. M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_11 · Cited by 32
A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop
Wu, D., Wang, Y.-C., Wang, L., Chen, C., & Lee, H. (2018) · Theranostics · doi:10.7150/thno.22048 · Cited by 34
Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis
Kim, J. H., Kim, H. S., & Kim, B. J. (2018) · Journal of Cancer · doi:10.7150/jca.24980 · Cited by 34
MET amplification increases the metastatic spread of EGFR-mutated NSCLC
Baldacci, S., Kherrouche, Z., Cockenpot, V., Stoven, L., Copin, M. C., Werkmeister, E., Marchand, N., Kyheng, M., Tulasne, D., & Cortot, A. B. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.008 · Cited by 34
Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non–Small-Cell Lung Cancer
Nokihara, H., Nishio, M., Yamamoto, N., Fujiwara, Y., Horinouchi, H., Kanda, S., Horiike, A., Ohyanagi, F., Yanagitani, N., Nguyen, L. T., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.018 · Cited by 34
Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells
Chang, L., Hu, Y. W., Fu, Y., Zhou, T., You, J., Du, J., Zheng, L., Cao, J., Ying, M., Dai, X., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.001 · Cited by 34
Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
Sun, D., Zhu, Y., Zhu, J., Tao, J., Wei, X., Wo, Y., & Hou, H. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00193-z · Cited by 36
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance
Gurden, M. D. J., Westwood, I. M., Faisal, A., Naud, S., Cheung, K.-M. J., McAndrew, C., Wood, A., Schmitt, J., Boxall, K. J., Mak, G. W.-Y., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3272 · Cited by 33
Multiplexed Exchange-PAINT imaging reveals ligand-dependent EGFR and Met interactions in the plasma membrane
Werbin, J. L., Avendaño, M. S., Becker, V., Jungmann, R., Yin, P., Danuser, G. M., & Sorger, P. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12257-y · Cited by 34
FBXW 7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
Xiao, Y., Yin, C., Wang, Y., Lv, H., Wang, W., Huang, Y., Pérez‐Losada, J., Snijders, A. M., Mao, J., & Zhang, P. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12200 · Cited by 34
Self-citation
Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET
Xia, S., Duan, W., Xu, M., Li, M., Tang, M., Wei, S., Lin, M., Li, E., Liu, W., & Wang, Q. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03015-w · Cited by 33
Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment
Yao, S., Liu, X., Feng, Y., Li, Y., Xiao, X., Han, Y., & Xia, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169101 · Cited by 33
Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance.
Sacco, J. J., & Clague, M. J. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.03.05 · Cited by 33
mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF
Ishikawa, D., Takeuchi, S., Nakagawa, T., Sano, T., Nakade, J., Nanjo, S., Yamada, T., Ebi, H., Zhao, L., Yasumoto, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062104 · Cited by 33
MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells
Boccaccio, C., Luraghi, P., & Comoglio, P. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1088 · Cited by 34
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
Noro, R., Seike, M., Zou, F., Soeno, C., Matsuda, K., Sugano, T., Nishijima, N., Matsumoto, M., Kitamura, K., Kosaihira, S., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1019-1 · Cited by 33
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
Suda, K., Bunn, P. A., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.003 · Cited by 33
Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation
Owusu, B. Y., Thomas, S., Venukadasula, P. K. M., Han, Z., Janetka, J. W., Galemmo, R. A., & Klampfer, L. (2017) · Oncotarget · doi:10.18632/oncotarget.18260 · Cited by 33
Evolution and Impact of Subclonal Mutations in Papillary Thyroid Cancer
Masoodi, T., Siraj, A. K., Siraj, S., Azam, S., Qadri, Z., Parvathareddy, S. K., Al-Sobhi, S. S., Aldawish, M., Alkuraya, F. S., & Al-Kuraya, K. S. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.09.026 · Cited by 32
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
Poels, K. E., Schoenfeld, A. J., Makhnin, A., Tobi, Y. Y., Wang, Y., Cabanos, H. F., Chakrabarti, S., Shi, M., Napoli, C., McDonald, T. O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23912-4 · Cited by 32
CMGC Kinases in Health and Cancer
Chowdhury, I. M., Dashi, G., & Keskitalo, S. (2023) · Cancers · doi:10.3390/cancers15153838 · Cited by 32
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
Ye, M., Zhang, X., Li, N., Zhang, Y., Jing, P., Chang, N., Wu, J., Ren, X., & Zhang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.6935 · Cited by 35
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
Baldacci, S., Mazières, J., Tomasini, P., Girard, N., Guisier, F., Audigier-Valette, C., Monnet, I., Wislez, M., Pérol, M., Dô, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21707 · Cited by 32
DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification
Camacho, C. V., Todorova, P. K., Hardebeck, M. C., Tomimatsu, N., del Alcazar, C. R. G., Ilcheva, M., Mukherjee, B., Mcellin, B. M., Vemireddy, V., Hatanpaa, K. J., et al. (2014) · Oncogene · doi:10.1038/onc.2014.29 · Cited by 32
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation
van Riel, S. J., Thunnissen, E., Heideman, D. A. M., Smit, E. F., & Biesma, B. (2012) · Annals of Oncology · doi:10.1093/annonc/mds525 · Cited by 32
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances
Guidi, L., Etessami, J. D., Valenza, C., Valdivia, A., Meric‐Bernstam, F., Felip, E., & Curigliano, G. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473148 · Cited by 38
Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
Rossi, A., Pasquale, R., Esposito, C., & Normanno, N. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.09.001 · Cited by 31
Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer
Nakata, A., & Gotoh, N. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.697155 · Cited by 31
Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution
Rosenthal, R., McGranahan, N., Herrero, J., & Swanton, C. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042516-011348 · Cited by 33
Targeting the Met pathway in lung cancer
Belalcazar, A., Azaña, D., Perez, C. A., Raez, L. E., & Santos, E. S. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.16 · Cited by 30
Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Yamaoka, T., Ohmori, T., Ohba, M., Arata, S., Kishino, Y., Murata, Y., Kusumoto, S., Ishida, H., Shirai, T., Hirose, T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0313 · Cited by 32
Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer
Quan, C., Chen, Y., Wang, X., Yang, D. L., Wang, Q., Huang, Y., Petersen, R. B., Liu, X., Zheng, L., Li, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.003 · Cited by 30
AKT inactivation causes persistent drug tolerance to EGFR inhibitors
Tetsu, O., Phuchareon, J., Eisele, D. W., Hangauer, M. J., & McCormick, F. P. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.022 · Cited by 31
Rationale and clinical use of multitargeting anticancer agents
Melisi, D., Piro, G., Tamburrino, A., Carbone, C., & Tortora, G. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.06.012 · Cited by 30
ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas
Song, X., Fan, P., Bantikassegn, A., Guha, U., Threadgill, D. W., VARMUS, H. E., & Politi, K. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-13-1625 · Cited by 30
Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist
Fasolo, A., Sessa, C., Gianni, L., & Broggini, M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds520 · Cited by 30
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
Attili, I., Karachaliou, N., Conte, P., Bonanno, L., & Rosell, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1508347 · Cited by 32
De Novo MET Amplification in Chinese Patients With Non–Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study
Song, Z., Wang, H., Yu, Z., Lu, P., Xu, C., Chen, G., & Zhang, Y. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.007 · Cited by 30
The novel phosphoinositide 3‐kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor
Sano, T., Takeuchi, S., Nakagawa, T., Ishikawa, D., Nanjo, S., Yamada, T., Nakamura, T., Matsumoto, K., & Yano, S. (2013) · International Journal of Cancer · doi:10.1002/ijc.28034 · Cited by 28
Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines
Katanasaka, Y., Kodera, Y., Yunokawa, M., Kitamura, Y., Tamura, T., & Koizumi, F. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.025 · Cited by 29
Effects of 1,25(OH)2D3 on Cancer Cells and Potential Applications in Combination with Established and Putative Anti-Cancer Agents
el Maaty, M. A. A., & Wölfl, S. (2017) · Nutrients · doi:10.3390/nu9010087 · Cited by 30
Introduction to Cancer Stem Cells: Past, Present, and Future
Bakhshinyan, D., Adile, A., Qazi, M. A., Singh, M., Kameda-Smith, M. M., Yelle, N., Chokshi, C., Venugopal, C., & Singh, S. K. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7401-6_1 · Cited by 30
Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
Keller, S., Zwingenberger, G., Ebert, K., Hasenauer, J., Wasmuth, J., Maier, D., Haffner, I., Schierle, K., Weirich, G., & Luber, B. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12170 · Cited by 29
A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
Liu, L., Qu, J., Heng, J., Zhou, C., Xiong, Y., Yang, H., Jiang, W., Zeng, L., Zhu, S., Zhang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722039 · Cited by 31
Targeting Receptor Tyrosine Kinases in Cancer
Köstler, W. J., & Zielinski, C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_10 · Cited by 26
LncRNA expression profiles of EGFR exon 19 deletions in lung adenocarcinoma ascertained by using microarray analysis
Wang, Y., Chen, W., Chen, J., Pan, Q., & Pan, J. (2014) · Medical Oncology · doi:10.1007/s12032-014-0137-y · Cited by 29
First steps in experimental cancer evolution
Taylor, T., Johnson, L. J., Jackson, R. W., Brockhurst, M. A., & Dash, P. R. (2013) · Evolutionary Applications · doi:10.1111/eva.12041 · Cited by 28
Mutation heterogeneity between primary gastric cancers and their matched lymph node metastases
Lee, H. H., Kim, S. Y., Jung, E. S., Yoo, J., & Kim, T. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0870-6 · Cited by 29
Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
Kou, J., Musich, P. R., Staal, B., Kang, L., Qin, Y. H., Yao, Z. Q., Zhang, B., Wu, W., Tam, A., Huang, A., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1628-y · Cited by 29
Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators
Marrocco, I., & Yarden, Y. (2023) · Cancers · doi:10.3390/cancers15205009 · Cited by 28
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics
Liao, Y.-Y., Tsai, C.-L., & Huang, H. (2025) · Cancers · doi:10.3390/cancers17030459 · Cited by 28
Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis
Tachibana, K., Minami, Y., Shiba‐Ishii, A., Kano, J., Nakazato, Y., Sato, Y., Goya, T., & Noguchi, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.07.008 · Cited by 28
Acquired Resistance in Oncogene-Addicted Non-Small-Cell Lung Cancer
Sini, C., Tuzi, A., Rossi, G., Russo, A., & Pezzuto, A. (2018) · Future Oncology · doi:10.2217/fon-2018-0097 · Cited by 29
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Strickler, J. H., LoRusso, P. M., Salgia, R., Kang, Y., Yen, C. J., Lin, C., Ansell, P. J., Motwani, M., Wong, S. L., Yue, H., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0529 · Cited by 28
Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling
Testa, U., Pelosi, E., & Castelli, G. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2017774 · Cited by 28
Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells
Song, X.-H., Yang, L., Zheng, X., Zhu, Q., Liao, X.-L., Liu, K., Zhang, W., Peng, Q., Zhu, Y., Zhao, L.-Y., et al. (2023) · MedComm · doi:10.1002/mco2.342 · Cited by 28
Evolution of targeted therapies in cancer: opportunities and challenges in the clinic
Santhosh, S., Kumar, P. R. G., Ramprasad, V. L., & Chaudhuri, A. (2015) · Future Oncology · doi:10.2217/fon.14.198 · Cited by 29
Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer
Han, J., Kim, J. Y., Lee, S. H., Yoo, N. J., & Choi, B. G. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.021 · Cited by 28
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
Galvani, E., Alfieri, R. R., Giovannetti, E., Cavazzoni, A., Monica, S. L., Galetti, M., Fumarola, C., Bonelli, M. A., Mor, M., Tiseo, M., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804547222 · Cited by 30
Engineered Bivalent Ligands to Bias ErbB Receptor-mediated Signaling and Phenotypes
Jay, S. M., Kurtagic, E., Alvarez, L. M., de Picciotto, S., Sánchez, E., Hawkins, J. F., Prince, R. N., Guerrero, Y. A., Treasure, C. L., Lee, R. T., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.221093 · Cited by 28
Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells
Giménez‐Xavier, P., Pros, E., Bonastre, E., Morán, S., Aza, A., Graña‐Castro, O., Goméz-López, G., Derdak, S. V., Dabad, M., Esteve‐Codina, A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0104 · Cited by 28
Reaction of plasma hepatocyte growth factor levels in non‐small cell lung cancer patients treated with EGFR‐TKIs
Tanaka, H., Kimura, T., Kudoh, S., Mitsuoka, S., Watanabe, T., Suzumura, T., Tachibana, K., Noguchi, M., Yano, S., & Hirata, K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25799 · Cited by 26
Advances in the management of melanoma: targeted therapy, immunotherapy and future directions
Dean, E. J., & Lorigan, P. C. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.124 · Cited by 27
Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer
Mohyeldin, M. M., Busnena, B. A., Akl, M. R., Dragoi, A. M., Cardelli, J. A., & Sayed, K. A. E. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.043 · Cited by 27
Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
Heydt, C., Michels, S. Y. F., Thress, K. S., Bergner, S., Wolf, J., & Buettner, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24624 · Cited by 27
Cancer heterogeneity and “The Struggle for Existence”: Diagnostic and analytical challenges
Horswell, S. D., Matthews, N., & Swanton, C. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.031 · Cited by 27
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
Tan, E.-H., Lim, W., Ahn, M., Ng, Q., Ahn, J. S., Tan, D. S., Sun, J., Han, M., Payumo, F. C., McKee, K., et al. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.427 · Cited by 27
Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies
Carrera, S., Buqué, A., Azkona, E., Aresti, U., Calvo, B., Sancho, A., Arruti, M., Nuño, M., Rubio, I., de Lobera, A. R., et al. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1143-9 · Cited by 26
Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer
Beck, T. N., Chikwem, A. J., Solanki-Patel, N., & Golemis, E. A. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00062.2014 · Cited by 26
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer
Bonanno, L., Jirillo, A., & Favaretto, A. G. (2011) · Current Drug Targets · doi:10.2174/138945011795528958 · Cited by 27
New Targets in Non–Small Cell Lung Cancer
Park, S. J., More, S., Murtuza, A., Woodward, B. D., & Husain, H. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.010 · Cited by 26
Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC
Xie, F., Li, P., Gong, J., Tan, H., & Ma, J.-T. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1754-7 · Cited by 26
BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment
Wang, F., Zhang, L., Sai, B., Wang, L., Zhang, X., Zheng, L., Tang, J., Li, G., & Xiang, J. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1665952 · Cited by 28
Receptor-type Protein Tyrosine Phosphatase β (RPTP-β) Directly Dephosphorylates and Regulates Hepatocyte Growth Factor Receptor (HGFR/Met) Function
Xu, Y., Xia, W., Baker, D. K., Zhou, J., Cha, H. C., Voorhees, J. J., & Fisher, G. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.212597 · Cited by 26
IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
Hussmann, D., Madsen, A. T., Jakobsen, K. R., Luo, Y., Sørensen, B. S., & Nielsen, A. L. (2017) · Oncotarget · doi:10.18632/oncotarget.16350 · Cited by 26
mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer
Chiang, C.-T., Demetriou, A. N., Ung, N. M., Choudhury, N., Ghaffarian, K., Ruderman, D., & Mumenthaler, S. M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.025 · Cited by 27
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma
Kong, L. R., Salleh, N. A. B. M., Ong, R., Tan, T. Z., Syn, N. L. X., Goh, R. M., Fhu, C. W., Tan, D. S. W., Iyer, N. G., Kannan, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15318-5 · Cited by 26
MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non–Small-Cell Lung Cancer
Camidge, D. R., & Davies, K. D. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00033 · Cited by 26
Targeting therapy-persistent residual disease
Sun, X., Wu, L. F., Altschuler, S. J., & Hata, A. N. (2024) · Nature Cancer · doi:10.1038/s43018-024-00819-9 · Cited by 25
Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Sano, Y., Hashimoto, E., Nakatani, N., Abe, M., Satoh, Y., Sakata, K., Fujii, T., Fujimoto-Ouchi, K., Sugimoto, M., Nagahashi, S., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0456 · Cited by 25
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
Presutti, D., Santini, S., Cardinali, B., Papoff, G., Lalli, C., Samperna, S., Fustaino, V., Giannini, G., & Ruberti, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143333 · Cited by 25
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
Spitaleri, G., Aliaga, P. T., Attili, I., Signore, E. D., Corvaja, C., Corti, C., Uliano, J., Passaro, A., & de Marinis, F. (2023) · Cancers · doi:10.3390/cancers15194779 · Cited by 24
Molecular Modeling of Exquisitely Selective c-Met Inhibitors through 3D-QSAR and Molecular Dynamics Simulations
Yuan, H., Zhuang, J., Hu, S., Li, H., Xu, J., Hu, Y., Xiong, X., Chen, Y., & Lu, T. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500268s · Cited by 25
Anti‐tumor activity of WK 88‐1, a novel geldanamycin derivative, in gefitinib‐resistant non‐small cell lung cancers with Met amplification
Jang, W., Jung, S., Kang, J. S., Jeong, J., Bae, M., Joo, S. H., Park, G. H., Kundu, J. K., Hong, Y., & Jeong, C. (2014) · Cancer Science · doi:10.1111/cas.12497 · Cited by 25
New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target?
Cloughesy, T. F., & Mischel, P. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2268 · Cited by 26
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
Santarpía, M., Altavilla, G., Salazar, M., Magrí, I., Pettineo, G., Benecchi, S., & Rosell, R. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.27 · Cited by 24
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients withFGF9upregulation may be resistant to anti-EGFR therapies
Mizukami, T., Togashi, Y., Naruki, S., Banno, E., Terashima, M., Velasco, M. A. D., Sakai, K., Yoneshige, A., Hayashi, H., Fujita, Y., et al. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22476 · Cited by 25
Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto, H., Yamada, T., Yano, S., Kondo, N., Hasegawa, S., & Tanaka, F. (2012) · PubMed · Cited by 25
Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway
Hong, S., Park, N.-S., Noh, M. H., Shim, J. A., Ahn, B., Kim, Y. S., Kim, D., Lee, H.-K., & Hur, D. Y. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.009 · Cited by 26
Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma
Johnson, J. S., Ascierto, M. L., Mittal, S., Newsome, D., Kang, L., Briggs, M., Tanner, K. G., Marincola, F. M., Berens, M. E., Woude, G. F. V., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0667-x · Cited by 24
Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges
Langer, C. J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.09.004 · Cited by 24
Epistatic interactions and drug response
Weigelt, B., & Reis-Filho, J. S. (2013) · The Journal of Pathology · doi:10.1002/path.4265 · Cited by 26

Authors: Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., Lindeman, N. I., Murphy, C., Akhavanfard, S., Yeap, B. Y., Xiao, Y., Capelletti, M., Iafrate, A. J., Lee, C., Christensen, J. G., Engelman, J. A., & Jänne, P. A.
Affiliations: Harvard University (US)
Dana-Farber Cancer Institute (US)
Guangdong General Hospital (CN)
Massachusetts General Hospital (US)
Chinese University of Hong Kong (HK)
Brigham and Women's Hospital (US)
Pfizer (United States) (US)
Corresponding author: Engelman, Jeffrey A.
ORCID: Wu, Yi-Long
Song, Youngchul
Dias-Santagata, Dora
Toschi, Luca
Mok, Tony
Sequist, Lecia
Lindeman, Neal I.
Akhavanfard, Sara
Yeap, Beow Y.
Capelletti, Marzia
Iafrate, A. John
Lee, Charles
Christensen, James G.
Engelman, Jeffrey A.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2010-01
Volume: 17
Issue: 1
Pages: 77-88
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2009.11.022
PMC: PMC2980857
OpenAlex: W1985264867
Cited by: 1,059
References: 37
Citations by year: 2026: 22 · 2025: 31 · 2024: 36 · 2023: 58 · 2022: 41 · 2021: 55 · 2020: 41 · 2019: 56 · 2018: 66 · 2017: 73 · 2016: 93 · 2015: 84 · 2014: 88 · 2013: 94 · 2012: 106
FWCI: 83.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1293 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Guangdong Provincial Hospital of Traditional Chinese Medicine
University of Hong Kong
Chinese University of Hong Kong
National Institutes of Health
National Cancer Institute (P50CA127003, R01CA140594, R01CA114465, P50CA090578, R01CA135257, K08CA120060, R01CA137008)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: MET amplification, EGFR mutation, non-small cell lung cancer, hepatocyte growth factor, clonal selection, combination therapy
MeSH terms: Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Gene Amplification, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins, Signal Transduction, Gene Expression, Polymerase Chain Reaction, Hepatocyte Growth Factor, In Situ Hybridization, Fluorescence, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Quinazolinones, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks